Vinay Prasad has regained his role as FDA’s chief medical and scientific officer, according to an update on the agency’s website.
FDA introduced the Rare Disease Evidence Principles to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
The U.S. House Appropriations Committee has voted along party lines passing a bill that maintains current funding levels for NIH and NCI as part of its Fiscal Year 2026 Labor, HHS, Education and Related Agencies spending bill.
At the end of July, after just a few months as director of the Center for Biologics Evaluation and Research, Vinay Prasad resigned.
To fight drug shortages that have dogged all of medicine—including oncology—for decades, the Trump administration is returning to a policy it first enacted during the president’s first term.
A federal judge ruled that the Trump Administration’s move to cut research funding to Harvard University was illegal—restoring more than $2 billion and all future grants to the institution.
FDA is shortening its timeline for publicizing Complete Response Letters, pledging to make them available to the public “promptly” after sponsors receive notice.
The American College of Obstetrics and Gynecology said it will no longer be accepting federal funding.
The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).
The Department of Health and Human Services has announced the start of a reduction in its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority.
